ELAVL1 and cancer: Recently, Zhou et al. reported that GPRC5A promoted PaCa cell growth and migration, and enhanced resistance to gemcitabine by regulating human antigen R (HuR), which was a key mediator of gemcitabine's efficacy in cancer cells 36.